In a world where Chronic Wounds affect about 2% of the global population leading to over 10 million amputations annually, imagine a simple "Band-Aid" that doesn't just cover a wound—it regenerates tissue from within, at a fraction of the cost of traditional therapies. That's the vision driving Asclepii, and it's closer to reality than you think.

As Founder & CEO of Asclepii, I've spent years in labs—from collaborating with Arnold Caplan (the father of mesenchymal stem cells) at Case Western Reserve University to developing Artemis, our platform of semi-synthetic cellular scaffolds.

These aren't your average bandages. They're engineered structures that optimize cell adhesion, growth, and vascularization, slashing production costs by eliminating expensive steps in tissue engineering.

Here's the problem we're solving: Regenerative therapies like cell-based treatments for chronic wounds are game-changers, but they're prohibitively expensive—often $45,000+ per patient—and require intense medical oversight. 

While we're primarily US-focused at this time, this could also work in emerging markets, where 80% of diabetes-related amputations occur, access is near zero. Artemis changes that by creating scalable, low-risk solutions that integrate seamlessly into everyday care.

The way I see it:

• Cell Adhesion Reimagined: Using bio-mimetic designs, our scaffolds mimic the body's extracellular matrix, allowing cells to "stick" and proliferate efficiently without costly bioreactors.

• Cost Reduction at Scale: By introducing nanotechnology, we can tackle antimicrobial resistance and cytotoxicity by implementing Ultra-Low concentrations, keeping manufacturing affordable without sacrificing efficacy.

• Familiarity, Reimagined: By applying advanced tech (NanoTech, BioTech) and materials science concepts (Surface / Organic Chemistry, BioPhysics) we can 'reinvent the wheel'—taking familiar, well-established products and compounds and re-engineering them at the nanoscale for maximal safety and efficacy. This means optimizing elements like silver integration for lower concentrations (reducing risks of cytotoxicity) while enhancing protease modulation, cell support, and overall performance in diverse wound environments.

What's next? Biomanufacturing revolutions will integrate AI for personalized scaffolds, potentially regenerating organs on demand. 

But we need more investment in DeepTech—Ohio alone represents untapped potential in this space.